DISHMAN CARBOGEN AMCIS share price has plunged 12% and is presently trading at Rs 172.8.
Meanwhile, the BSE HEALTHCARE index is at 41,000.5 (down 0.1%).
Among the top losers in the BSE HEALTHCARE index today are Divis Laboratories (down 2.2%) and ASTRAZENECA PHARMA (down 1.7%).
AJANTA PHARMA (up 6.4%) and ALEMBIC PHARMA (up 1.7%) are among the top gainers today.
Over the last one year, DISHMAN CARBOGEN AMCIS has moved up from Rs 157.8 to Rs 172.8, registering a gain of Rs 15.1 (up 9.5%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,819.2 to 41,000.5, registering a gain of 47.4% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 129.7%), GSK Pharma (up 99.8%) and SUVEN PHARMACEUTICALS (up 98.5%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 78,980.1 .
The top gainers among the BSE Sensex today are Tech Mahindra (up 1.0%) and M&M (up 0.9%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 24,146.7 . Hindalco and HCl Tech. are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,401.9 to 78,980.1, registering a gain of 13,578.2 points (up 20.8%).
DISHMAN CARBOGEN AMCIS net profit grew 1.1% YoY to Rs -699 million for the quarter ended March 2024, compared to a loss of Rs 707 million a year ago. Net sales rose 5.8% to Rs 6,547 million during the period as against Rs 6,186 million in January-March 2023.
For the year ended March 2023, DISHMAN CARBOGEN AMCIS reported 265.5% decrease in net profit to Rs -298 million compared to net profit of Rs 180 million during FY22. Revenue of the company grew 12.7% to Rs 24,129 million during FY23.
The current Price to earnings ratio of DISHMAN CARBOGEN AMCIS, based on rolling 12 month earnings, stands at -17.7.
Equitymaster requests your view! Post a comment on "DISHMAN CARBOGEN AMCIS Plunges 12%; BSE HEALTHCARE Index Down 0.1%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!